Skip to content
Download PDF

Hypoglycemia

Chapter 418 | Part 12: Endocrinology and Metabolism · Part 12 – Endocrinology & Metabolism · Chapter 418

Key Clinical Points

  1. Whipple's triad defines clinical hypoglycemia: (1) symptoms consistent with hypoglycemia, (2) low plasma glucose measured by a precise method, and (3) relief of symptoms after raising the plasma glucose level.
  2. Normal fasting plasma glucose is ≈70 mg/dL (3.9 mmol/L); lower levels occur naturally in pregnancy, during prolonged fasting (>24 h), or late after a meal.
  3. Hypoglycemia triggers pro-inflammatory, pro-coagulant, and pro-atherothrombotic responses, increasing platelet aggregation and risk of cardiovascular events.
  4. Counterregulation involves three main defenses: \downarrow Insulin (1st), \uparrow Glucagon (2nd), and \uparrow Epinephrine (3rd).
  5. Hypoglycemia-associated autonomic failure (HAAF) results from repeated iatrogenic hypoglycemia, leading to 'hypoglycemia unawareness' and 'defective counterregulation'.
  6. Insulinoma diagnosis requires: Insulin ≥3 μU/mL (≥18 pmol/L), C-peptide ≥0.6 ng/mL (≥0.2 nmol/L), and Proinsulin ≥5.0 pmol/L when glucose <55 mg/dL (<3.0 mmol/L).
  7. Critical care glycemic targets are 140–180 mg/dL to reduce mortality risk from severe hypoglycemia.
  8. Alcohol-induced hypoglycemia occurs after several days of binge drinking with concurrent food deprivation and glycogen depletion.
  9. T2DM patients on insulin have high rates of hypoglycemia (approaching 70%), even at HbA1c levels of 8–10%.
  10. Metformin, thiazolidinediones, α-glucosidase inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and DPP-IV inhibitors do not cause hypoglycemia unless combined with a sulfonylurea, glinide, or insulin.

1. DEFINITION & OVERVIEW

• Definition: A condition where plasma glucose concentration falls below the physiologic range, leading to insufficient blood-to-brain glucose transport to support brain energy metabolism and function. • Whipple's Triad: • Symptoms consistent with hypoglycemia • Low plasma glucose concentration measured with a precise method • Relief of symptoms after plasma glucose level is raised • Glucose Thresholds: • Normal fasting limit: ≈70 mg/dL (3.9 mmol/L) • Exceptions (lower levels occur normally): Late after a meal, during pregnancy, and during prolonged fasting (>24 h). • Clinical Significance: Severe hypoglycemia can cause serious morbidity and increase the risk for cardiovascular events and mortality; suspect in patients with confusion, altered consciousness, or seizures.

2. EPIDEMIOLOGY

• Type 1 Diabetes Mellitus (T1DM): • Average of two episodes of symptomatic hypoglycemia per week. • At least one episode of severe, at least temporarily disabling hypoglycemia each year. • Estimated 6–10% mortality rate due to hypoglycemia. • Type 2 Diabetes Mellitus (T2DM): • Prevalence in insulin-requiring T2DM: ≈70%. • Higher prevalence than T1DM due to higher population volume. • Risk of cardiovascular and cerebrovascular morbidity for up to 1 year after a severe event. • Glycemic Control Targets: • Severe hypoglycemia can occur at HbA1c values of 8–10% in both T1DM and T2DM. • Critical care setting target: 140–180 mg/dL.

3. ETIOLOGY & PATHOPHYYSOLOGY

• General Causes of Hypoglycemia: • Drugs (Insulin, insulin secretagogues, alcohol). • Critical illness (Hepatic, renal, or cardiac failure; sepsis; inanition). • Hormone deficiency (Cortisol, growth hormone). • Non-islet cell tumors (e.g., mesenchymal tumors). • Endogenous hyperinsulinism (Insulinoma, nesidioblastosis). • Other: Post-gastric bypass, insulin autoimmune hypoglycemia, antibody to insulin/receptor. • Counterregulatory Mechanisms: • \downarrow Insulin (1st Defense): Primary glucose regulatory factor; occurs at 4.4–4.7 mmol/L (80–85 mg/dL). Increases lipolysis and FFA. • \uparrow Glucagon (2nd Defense): Primary counterregulatory factor; occurs at 3.6–3.9 mmol/L (65–70 mg/dL). • \uparrow Epinephrine (3rd Defense): Critical when glucagon is deficient; occurs at 3.6–3.9 mmol/L (65–70 mg/dL). Increases lipolysis and production of glycerol/fatty acids. • Cortisol & Growth Hormone: Support glucose production but are not critical for acute hypoglycemia (response reduced by ≈80% compared to epinephrine). • Table 418-2 Summary (Physiologic Responses): • \downarrow Insulin (80–85 mg/dL) → Primary regulator; increases lipolysis. • \uparrow Glucagon (65–70 mg/dL) → Primary counterregulatory factor. • \uparrow Epinephrine (65–70 mg/dL) → Critical when glucagon is deficient. • Symptoms (50–55 mg/dL) → Recognition of hypoglycemia; triggers behavioral defense (food ingestion). • \downarrow Cognition (<50 mg/dL) → Compromises behavioral defense. • Hypoglycemia-Associated Autonomic Failure (HAAF): • Pathophysiology: Result of repeated iatrogenic hypoglycemia leading to blunted sympathoadrenal responses. • Mechanism 1: \downarrow Adrenomedullary epinephrine → Defective glucose counterregulation. • Mechanism 2: \downarrow Sympathetic neural responses → Hypoglycemia unawareness. • Clinical Risk: Patients with HAAF are at ≥25-fold greater risk of severe iatrogenic hypoglycemia during intensive therapy.

Table 418-1 Summary (Causes Across Lifespan)

• Ill or Medicated Individuals: • Drugs: Insulin, insulin secretagogues, alcohol. • Critical Illness: Hepatic/renal/cardiac failure, sepsis, inanition. • Hormone Deficiency: Cortisol, growth hormone. • Non-islet tumors (e.g., mesenchymal). • Seemingly Well Individuals: • Endogenous hyperinsulinism: Insulinoma, nesidioblastosis, noninsulinoma pancreatogenous hypoglycemia. • Other: Post-gastric bypass, insulin autoimmune hypoglycemia, antibody to insulin/receptor, GLP-1 receptor agonists + insulin/secretagogues, exercise, prolonged fasting, pregnancy.

4. CLINICAL FEATURES

• Neuroglycopenic Manifestations: • Result of CNS glucose deprivation. • Features: Behavioral changes, confusion, fatigue, seizure, loss of consciousness, cardiac arrhythmias, death. • Neurogenic (Autonomic) Manifestations: • Result from sympathoadrenal discharge. • Adrenergic: Palpitations, tremor, anxiety. • Cholinergic: Sweating, hunger, paresthesias.

5. DIFFERENTIAL DIAGNOSIS

• Drug-Induced Hypoglycemia: • Insulin/Secretagogues: Suppress production, increase utilization. • Alcohol: Blocks gluconeogenesis; requires several days of binge + food deprivation. • Others: ACE inhibitors, β-blockers, Quinolones, Indomethacin. • Critical Illness: • Hepatic failure: Loss of primary site of glucose production. • Renal failure: Reduced clearance of insulin; reduced mobilization of precursors. • Sepsis: Cytokine-induced increased glucose utilization. • Starvation: Minimal counterregulatory response due to brain use of lactate/ketones. • Hormone Deficiency: • Cortisol: Associated with impaired gluconeogenesis and low precursors. • Growth Hormone: Can cause hypoglycemia in children. • Non-beta Cell Tumors: • Often 'big IGF-II' production; insulin levels are suppressed appropriately during hypoglycemia. • Endogenous Hyperinsulinism: • Insulinoma (primary β-cell tumor). • Nesidioblastosis (functional β-cell disorder). • Noninsulinoma pancreatogenous hypoglycemia.

6. INVESTIGATIONS & DIAGNOSIS

  1. Initial Assessment: Evaluate for Whipple's Triad to confirm clinical significance.
  2. Laboratory Evaluation (for suspected Hyperinsulinism): • Measure Plasma Insulin, C-peptide, and Proinsulin during hypoglycemia. • Criteria for hyperinsulinism (when glucose <55 mg/dL): • Insulin ≥3 μU/mL (≥18 pmol/L) • C-peptide ≥0.6 ng/mL (≥0.2 nmol/L) • Proinsulin ≥5.0 pmol/L
  3. Imaging: Used for localization of tumors (e.g., insulinoma) if hyperinsulinism is confirmed.

7. MANAGEMENT & TREATMENT

  1. Risk Reduction: • Identify and remove offending agents (e.g., alcohol, specific drugs). • Adjust insulin/secretagogue dosages.
  2. Pharmacologic Treatment: • Immediate treatment of acute hypoglycemia (glucose administration). • Adjustment of maintenance therapy to avoid recurrence.
  3. Surgical Intervention: • Indicated for confirmed insulinoma or other localized tumors.
  4. Monitoring: • Monitor for HAAF signs (hypoglycemia unawareness) in patients with repeated episodes.

8. PROGNOSIS & COMPLICATIONS

• Cardiovascular Risk: Hypoglycemia triggers pro-inflammatory, pro-coagulant, and pro-atherothrombotic responses; increases platelet aggregation and reduces nitric oxide-mediated vasodilation. • HAAF Reversibility: HAAF is a functional disorder (potentially reversible) but distinct from structural/irreversible diabetic autonomic neuropathy.

9. SPECIAL CONSIDERATIONS

• Critical Care: Target 140–180 mg/dL to reduce mortality. • Pregnancy: Lower glucose levels may occur normally; hypoglycemia is rare unless drug-related. • Renal/Hepatic Impairment: Reduced insulin clearance and reduced mobilization of gluconeogenic precursors lead to hypoglycemia.

10. KEY PEARLS & CLINICAL TRAPS

• Diagnostic Clue: If a patient is 'seemely well' and has hypoglycemia, focus on endogenous hyperinsulinism (Insulinoma) or accidental/malicious causes. • Exclusion Criteria: Unless Whipple's triad is present, it is rare to conclude a hypoglycemic disorder exists in the absence of drug-treated diabetes or pregnancy. • HAAF Warning: Patients with HAAF are at ≥25-fold higher risk of severe hypoglycemia during intensive therapy.

Reference Tables

TABLE 418-1 Causes of Hypoglycemia Across the Life Span Ill or Medicated Individual 1. Drugs

Harrison's 22e, p.3231

  • Ill or Medicated Individual
    1. Drugs
      Insulin or insulin secretagogues
      Alcohol
      Others
      2. Critical illness
      Hepatic, renal, or cardiac failure
      Sepsis
      Inanition
      3. Hormone deficiency
      Cortisol
      Growth hormone
      Glucagon and epinephrine (in insulin-deficient diabetes)
      4. Non–islet cell tumor (e.g., mesenchymal tumors)
  • Seemingly Well Individual
    1. Endogenous hyperinsulinism
      Insulinoma
      Functional β-cell disorders (nesidioblastosis)
      Noninsulinoma pancreatogenous hypoglycemia
      Post–gastric bypass hypoglycemia
      Insulin autoimmune hypoglycemia
      Antibody to insulin
      Antibody to insulin receptor
      GLP-1 receptor agonists in combination with insulin and/or insulin
      secretagogues
      Insulin secretagogues
      Other
      6. Disorders of gluconeogenesis and fatty acid oxidation
      7. Exercise
      8. Accidental, surreptitious, or malicious hypoglycemia
      9. Prolonged fasting
      10. Pregnancy

TABLE 418-2 Physiologic Responses to Decreasing Plasma Glucose Concentrations RESPONSE ↓ Insulin ↑ Glucagon ↑…

Harrison's 22e, p.3232

RESPONSE GLYCEMIC THRESHOLD,
mmoL/L (mg/dL)		 PHYSIOLOGIC ↓ EFFECTS ROLE IN PREVENTION OR CORRECTION OF
HYPOGLYCEMIA (GLUCOSE COUNTERREGULATION)
↓ Insulin 4.4–4.7 (80–85) ↑ R (↓ R), increased lipolysis; ↑ FFA
a d
↑ Glycerol		 Primary glucose regulatory factor/first defense against
hypoglycemia
3.6–3.9 (65–70) ↑ R
a
↑ Epinephrine 3.6–3.9 (65–70) ↑ R, ↓ R, increased lipolysis;
a c
↑ FFA and glycerol		 Third defense against hypoglycemia; critical when
glucagon is deficient
3.6–3.9 (65–70) ↑ R, ↓ R
a c
Symptoms 2.8–3.1 (50–55) Recognition of hypoglycemia Prompt behavioral defense against hypoglycemia
(food ingestion)
<2.8 (<50) —